Tapentadol

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Diabetic Peripheral Neuropathic Pain, Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • Severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options
Product first approved 2012FDA label
JP
  • Management of moderate to severe pain in various types of cancer
Product first approved 2014PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (33)
Diabetic Peripheral Neuropathic Pain
NCT01063868 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-01 – 2010-06 · Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
What this study did
Other / comorbidity
NCT02081391 · Grünenthal GmbH
2015-02-19 – 2019-03-14 · Acute Pain
What this study did
NCT02604446 · St. Olavs Hospital
2015-09 – 2019-02 · Joint Diseases
What this study did
NCT01264887 · Grünenthal GmbH
2011-03 – 2014-05 · Cancer, Chronic Pain, Pain
What this study did
NCT01813890 · Janssen-Cilag International NV
2013-01 – 2014-01 · Hallux Valgus
What this study did
NCT01516008 · Janssen Research & Development, LLC
2012-01 – 2013-02 · Hallux Valgus
What this study did
NCT01165281 · Janssen Research & Development, LLC
2010-08 – 2012-08 · Pain
What this study did
NCT00472303 · Grünenthal GmbH
2007-07 – 2012-06 · Tumor, Pain
What this study did
NCT01309386 · Janssen Pharmaceutical K.K.
2010-08 – 2012-01 · Neoplasms
What this study did
NCT00986258 · Grünenthal GmbH
2009-10-30 – 2011-01 · Pain, Chronic Pain, Low Back Pain, Neuropathic Pain, Nociceptive Pain
What this study did
NCT00986180 · Ortho-McNeil Janssen Scientific Affairs, LLC
2009-09 – 2010-12 · Pain, Back Pain, Low Back Pain, Back Pain With Radiation
What this study did
NCT00771758 · Ortho-McNeil Janssen Scientific Affairs, LLC
2008-09 – 2009-12 · Back Pain
What this study did
NCT00784277 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-10 – 2009-07 · Joint Diseases, Arthritis, Osteoarthritis
What this study did
NCT00487435 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2007-06 – 2009-06 · Pain, Osteoarthritis, Low Back Pain
What this study did
NCT00505414 · Grünenthal GmbH
2007-06 – 2009-05 · Pain, Neoplasm, Cancer
What this study did
NCT00421928 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2007-01 – 2008-12 · Osteoarthritis, Knee, Pain
What this study did
NCT00613938 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-02 – 2008-10 · Arthralgia, Bunion, Hallux Valgus, Pain
What this study did
NCT00361504 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-11 – 2008-07 · Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
What this study did
NCT00486811 · Grünenthal GmbH
2007-06 – 2008-07 · Pain, Knee Osteoarthritis
What this study did
NCT00449176 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2007-02 – 2008-05 · Low Back Pain
What this study did
NCT00594516 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2007-12 – 2008-05 · Low Back Pain
What this study did
NCT00478023 · Grünenthal GmbH
2007-05 – 2008-04 · Hysterectomy, Postoperative
What this study did
NCT00609466 · Grünenthal GmbH
2007-09 – 2008-02 · Bunionectomy, Pain, Postoperative Pain, Acute Pain
What this study did
NCT00361582 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-10 – 2007-08 · Osteoarthritis, Pain Assessment, Arthralgia
What this study did
NCT00364546 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-07 – 2007-07 · Osteoarthritis, Pain Intensity Assessment, Arthralgia, Sciatica, Low Back Pain
What this study did
NCT00364247 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
est. completion 2007-05 · Arthralgia, Bunion, Hallux Valgus, Pain Assessment, Tapentadol
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02151682 · Grünenthal GmbH
2015-04-29 – 2018-10-15 · Pain
What this study did
Phase 2 (9)
Diabetic Peripheral Neuropathic Pain
NCT01124617 · Janssen Pharmaceutical K.K.
2010-06 – 2011-04 · Pain, Diabetic Neuropathies, Neuralgia, Postherpetic Neuralgia
What this study did
Other / comorbidity
NCT02221674 · Grünenthal GmbH
2014-11-05 – 2016-11-03 · Moderate to Severe Acute Postoperative Pain
What this study did
NCT01729728 · Grünenthal GmbH
2012-11 – 2014-02 · Postoperative Pain, Acute Pain
What this study did
NCT01134536 · Janssen Research & Development, LLC
2011-10 – 2013-03 · Pain, Postoperative, Postoperative Pain
What this study did
NCT01435577 · Grünenthal GmbH
2011-09 – 2012-02 · Bunion, Pain
What this study did
NCT01124604 · Janssen Pharmaceutical K.K.
2010-04 – 2010-12 · Pain, Low Back Pain, Back Pain, Osteoarthritis, Knee
What this study did
NCT00805142 · Janssen Pharmaceutical K.K.
2008-11 – 2009-07 · Pain, Cancer
What this study did
NCT00806247 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-01 – 2005-08 · Pain, Postoperative Pain
What this study did
NCT00745069 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-07 – 2005-08 · Osteoarthitis, Chronic Pain, Knee Pain
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03121547 · Frederiksberg University Hospital
2015-05-19 – 2016-01-29 · Opioid Induced Motor Disturbances
What this study did
Phase 1 (12)
Other / comorbidity
NCT01615510 · University Hospital Schleswig-Holstein
2012-10 – 2013-03 · Pain, Hyperalgesia, Allodynia
What this study did
NCT01309425 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-02 – 2011-05 · Healthy Volunteer
What this study did
NCT01273532 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-12 – 2011-03 · Healthy Volunteer
What this study did
NCT01273506 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-12 – 2011-02 · Healthy Volunteer
What this study did
NCT01900587 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-07 – 2010-08 · Healthy
What this study did
NCT01981278 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-07 – 2010-08 · Healthy
What this study did
NCT02019485 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-07 – 2010-08 · Healthy
What this study did
NCT01877226 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-09 – 2008-10 · Healthy
What this study did
NCT03979989 · Grünenthal GmbH
2005-09-28 – 2005-11-16 · Pharmacokinetic
What this study did
NCT03956134 · Grünenthal GmbH
2005-04 – 2005-06 · Pharmacokinetics
What this study did
NCT03951402 · Grünenthal GmbH
2003-03 – 2003-08 · Prolonged QTc Interval, Pharmacokinetic
What this study did
Phase 4 (9)
Other / comorbidity
NCT06269770 · University of Thessaly
2023-05-01 – 2025-06-01 · Total Knee Replacement, Post-operative Pain, Chronic Pain
What this study did
NCT05999890 · Kempegowda Institute of Medical Sciences, Bangalore
2021-07-05 – 2021-12-30 · Lower Limb Fracture
What this study did
NCT03604354 · All India Institute of Medical Sciences, Bhubaneswar
2018-08-01 – 2020-05-19 · Osteoarthritis, Knee
What this study did
NCT03314792 · Oslo University Hospital
2017-12-04 – 2019-02-28 · Pain, Postoperative, Pain Uterus, Pain, Acute, Opioid Use, Analgesics, Antipyretics, and Antirheumatics Causing Adverse Effects in Therapeutic Use, Visceral Pain
What this study did
NCT01838616 · Grünenthal GmbH
2013-04 – 2014-01 · Back Pain, Low Back Pain, Neuropathic Pain
What this study did
NCT01458015 · University Hospital Schleswig-Holstein
2011-10 – 2013-11 · Peripheral Neuropathy
What this study did
NCT01631513 · Janssen Scientific Affairs, LLC
2012-08 – 2013-04 · Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
What this study did
NCT01352741 · Grünenthal GmbH
2011-03 – 2012-01 · Low Back Pain, Neuropathic Pain
What this study did
NCT01500317 · Mayo Clinic
2011-05 – 2011-12 · Effects of 2 Mu-opiates on Gastrointestinal Transit
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT07320781 · Shaukat Khanum Memorial Cancer Hospital & Research Centre
2024-11-15 – 2025-10-10 · Breast Cancer
What this study did
NCT04718116 · Aretaieion University Hospital
2022-11-01 – 2024-12-31 · Postoperative Pain, Surgery, Pain, Postoperative, Pain, Acute, Pain, Chronic, Pain, Procedural, Pain, Neuropathic, Analgesia
What this study did
NCT07587645 · ISSSTE Hospital Regional "Gral. Ignacio Zaragoza"
2024-06-19 – 2024-07-05 · Acute Postoperative Pain, Lower Limb Surgery
What this study did
NCT03351517 · All India Institute of Medical Sciences, Bhubaneswar
2017-11-01 – 2018-09-07 · Analgesia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Other / comorbidity
NCT01725087 · Tris Pharma, Inc.
2012-11 – 2014-07 · Low Back Pain
What this study did

Competitive landscape

This drug's own stage for Diabetic Peripheral Neuropathic Pain: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tapentadol: this drugApprovedSmall moleculeMu-opioid receptor and norepinephrine transporter (NET)Reliable signal
NCT01041859: Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12 (Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)): DB Tapentadol ER 0.28 units on a scale (Standard Deviation 2.04) vs DB Placebo 1.3 units on a scale (Standard Deviation 2.43)
NCT00455520: Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12 (Baseline and 12 weeks): Tapentadol ER -0.1 scores on a scale (Standard Deviation 1.69) vs Placebo 1.3 scores on a scale (Standard Deviation 2.41)
Capsaicin (Qutenza)ApprovedSmall moleculeTRPV1 (transient receptor potential vanilloid 1) channelReliable signal
NCT01533428: Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8 (Baseline to between Weeks 2 to 8): Capsaicin 8% -27.44% (Standard Deviation 26.79) vs Placebo -20.85% (Standard Deviation 28.92)
NCT01478607: Norfolk QOL-DN total score change from baseline to end of study: 30 min capsaicin + SOC -27.6% (mean difference vs SOC alone -20.9, 90% CI -31.7 to -10.1); 60 min capsaicin + SOC -32.8% (mean difference vs SOC alone -26.1, 90% CI -36.8 to -15.4); SOC alone -6.7%.
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)Partial signal
NCT01179672: Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score (Baseline, 12 weeks): Duloxetine -2.4 units on a scale (Standard Error 0.14) vs Placebo -1.97 units on a scale (Standard Error 0.14)
NCT00408993: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score (Baseline and 12 weeks): Duloxetine -2.69 units on a scale (Standard Error 0.19) vs Placebo -2.31 units on a scale (Standard Error 0.18) missed
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signalNo reviewed efficacy summary in this indication
CrisugabalinPhase 3Small moleculeα2δ-1 subunit of voltage-gated calcium channelsReliable signal
NCT04647773: Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001)
MirogabalinPhase 3Small moleculeα2δ-1 subunit of voltage-gated calcium channelsPartial signal
NCT04094662: Average Daily Pain Score (ADPS) change from baseline to week 14, LS mean difference vs placebo: -0.39 (95% CI: -0.74, -0.04), p = 0.0301
NCT02318706: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain (Baseline to Week 14 (post-dose 1 [15 mg QD] and post-dose 2 [20 mg and 30 mg])): DS-5565 15mg QD — Week 1: -0.39 units on a scale (Standard Deviation 0.67); Week 2: -0.6 units on a scale (Standard Deviation 0.9); Week 3: -0.78 units on a scale (Standard Deviation 1.02); Week 4: -0.87 units on a scale (Standard Deviation 1.13); Week 5: -0.97 units on a scale (Standard Deviation 1.2); Week 6: -1.01 units on a scale (Standard Deviation 1.32); Week 7: -1.06 units on a scale (Standard Deviation 1.4); Week 8: -1.07 units on a scale (Standard Deviation 1.49); Week 9: -1.13 units on a scale (Standard Deviation 1.49); Week 10: -1.19 units on a scale (Standard Deviation 1.56); Week 11: -1.23 units on a scale (Standard Deviation 1.57); Week 12: -1.24 units on a scale (Standard Deviation 1.6); Week 13: -1.27 units on a scale (Standard Deviation 1.63); Week 14: -1.34 units on a scale (Standard Deviation 1.74) | DS-5565 20 mg (10 mg BID) — Week 1: -0.4 units on a scale (Standard Deviation 0.85); Week 2: -0.72 units on a scale (Standard Deviation 1.12); Week 3: -0.84 units on a scale (Standard Deviation 1.22); Week 4: -0.94 units on a scale (Standard Deviation 1.38); Week 5: -1.06 units on a scale (Standard Deviation 1.5); Week 6: -1.13 units on a scale (Standard Deviation 1.52); Week 7: -1.13 units on a scale (Standard Deviation 1.59); Week 8: -1.26 units on a scale (Standard Deviation 1.59); Week 9: -1.27 units on a scale (Standard Deviation 1.56); Week 10: -1.33 units on a scale (Standard Deviation 1.65); Week 11: -1.36 units on a scale (Standard Deviation 1.64); Week 12: -1.36 units on a scale (Standard Deviation 1.67); Week 13: -1.43 units on a scale (Standard Deviation 1.72); Week 14: -1.47 units on a scale (Standard Deviation 1.69) | DS-5565 30 mg (15 mg BID) — Week 1: -0.6 units on a scale (Standard Deviation 1.01); Week 2: -1 units on a scale (Standard Deviation 1.27); Week 3: -1.33 units on a scale (Standard Deviation 1.49); Week 4: -1.43 units on a scale (Standard Deviation 1.63); Week 5: -1.48 units on a scale (Standard Deviation 1.68); Week 6: -1.58 units on a scale (Standard Deviation 1.73); Week 7: -1.57 units on a scale (Standard Deviation 1.72); Week 8: -1.53 units on a scale (Standard Deviation 1.79); Week 9: -1.63 units on a scale (Standard Deviation 1.76); Week 10: -1.67 units on a scale (Standard Deviation 1.83); Week 11: -1.69 units on a scale (Standard Deviation 1.8); Week 12: -1.82 units on a scale (Standard Deviation 1.84); Week 13: -1.85 units on a scale (Standard Deviation 1.93); Week 14: -1.88 units on a scale (Standard Deviation 1.88) vs Placebo — Week 1: -0.26 units on a scale (Standard Deviation 0.79); Week 2: -0.46 units on a scale (Standard Deviation 0.96); Week 3: -0.57 units on a scale (Standard Deviation 1.08); Week 4: -0.7 units on a scale (Standard Deviation 1.12); Week 5: -0.84 units on a scale (Standard Deviation 1.17); Week 6: -0.92 units on a scale (Standard Deviation 1.25); Week 7: -1.03 units on a scale (Standard Deviation 1.31); Week 8: -1.09 units on a scale (Standard Deviation 1.39); Week 9: -1.16 units on a scale (Standard Deviation 1.42); Week 10: -1.18 units on a scale (Standard Deviation 1.44); Week 11: -1.25 units on a scale (Standard Deviation 1.46); Week 12: -1.28 units on a scale (Standard Deviation 1.5); Week 13: -1.32 units on a scale (Standard Deviation 1.55); Week 14: -1.37 units on a scale (Standard Deviation 1.6)
Suzetrigine (Journavx)Phase 3Small moleculeVoltage-gated sodium channel NaV1.8Partial signal
NCT05660538: Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Pregabalin -2.09 units on a scale (95% CI -2.65--1.52) vs Suzetrigine (SUZ): Low Dose -2.18 units on a scale (95% CI -2.94--1.41) vs Suzetrigine (SUZ): Mid Dose -2.11 units on a scale (95% CI -2.67--1.55) vs Suzetrigine (SUZ): High Dose -2.26 units on a scale (95% CI -2.82--1.70)
HL-1186Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
JMKX000623Phase 2Small moleculeVoltage-gated sodium channel NaV1.8Partial signalNo reviewed efficacy summary in this indication
LY4065967Phase 2Small moleculeAngiotensin II type 2 receptor (AT2R) (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Nispomeben (NRD135S.E1)Phase 2Small molecule—Partial signal
NCT05480228: Primary (11-point NRS pain, change from baseline to week 12): NRD135S.E1 80 mg/day -1.90 (SD 2.38, n=61) vs placebo -1.94 (SD 2.27, n=61); no statistical analysis posted missed
NCT02345291: Placebo-corrected change in weekly mean daily pain intensity (11-point NRS) from run-in to Week 3 (mITT, N=86): -0.42 points for 10 mg (95% CI -1.50, 0.66; p=0.438); -0.82 points for 40 mg (95% CI -1.58, -0.07; p=0.034); -0.66 points for 150 mg (95% CI -1.35, 0.03; p=0.061). missed
PilavapadinPhase 2Small moleculeAP2-associated kinase 1 (AAK1)Partial signal
NCT06203002: Change from baseline to Week 8 in ADPS: -1.74 (10 mg), -1.70 (20 mg/10 mg titration), -1.38 (20 mg), vs -1.31 (placebo); overall primary endpoint p=0.11 (not significant, as the statistical plan required all arms to separate from placebo) missed
NCT04455633: Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating Scale (Baseline (Week 2 of the Run-in period) to Week 6): LX9211 100 mg/10 mg -1.39 score on a scale (95% CI -1.77 to -1.01) | LX9211 200 mg/20 mg -1.27 score on a scale (95% CI -1.66 to -0.88) vs Placebo -0.72 score on a scale (95% CI -1.08 to -0.36)
Pirenzepine (topical)Phase 2Small moleculeMuscarinic M1 receptor (antagonist)Partial signalFeatured results are safety only in this race
VX-993Phase 2Small moleculeVoltage-gated sodium channel NaV1.8not yet gradedNo reviewed efficacy summary in this indication
AJH-2947
Phase 1(overall)
Small molecule—Partial signalNo reviewed efficacy summary in this indication
HRS-2129Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
QR-333DiscontinuedBotanical—not yet gradedNo reviewed efficacy summary in this indication
TanezumabDiscontinuedMonoclonal antibodyNerve growth factor (NGF)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

December 2025ApprovalFDA updates Boxed Warning on Tapentadol (NDA200533)
US, FDA · FDA · Source ↗